#1 Clinical Trials Search in Europe

Io102 Hydrochloride

This article explores the use of IO102 Hydrochloride, a novel immunotherapy drug, in clinical trials for patients with melanoma and head and neck cancer. The trials aim to evaluate the safety, efficacy, and potential benefits of IO102 Hydrochloride, either alone or in combination with other treatments, in improving outcomes for patients with these challenging cancers.

Table of Contents

What is IO102 HYDROCHLORIDE?

IO102 HYDROCHLORIDE, also known as IDOlong hydrochloride or Imsamotide hydrochloride, is an innovative immunotherapy drug being developed for cancer treatment[1]. It is a peptide-based therapy, which means it’s made from small proteins that can stimulate the immune system to fight cancer cells[2].

How Does IO102 HYDROCHLORIDE Work?

IO102 HYDROCHLORIDE works by targeting and inhibiting an enzyme called IDO (Indoleamine 2,3-dioxygenase). IDO is often overexpressed in cancer cells and helps them evade the immune system. By blocking IDO, IO102 HYDROCHLORIDE aims to reduce immune suppression induced by IDO-positive cells, allowing the body’s immune system to better recognize and attack cancer cells[3].

What Conditions Does IO102 HYDROCHLORIDE Treat?

Current clinical trials are investigating IO102 HYDROCHLORIDE for the treatment of several types of cancer, including:

  • Melanoma: A type of skin cancer[1]
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN): A type of cancer that affects the mouth, nose, and throat[2]

These cancers were chosen for initial trials due to their responsiveness to immunotherapy treatments.

Current Clinical Trials

Several clinical trials are currently underway to evaluate the safety and efficacy of IO102 HYDROCHLORIDE:

  1. Phase II Trial for Resectable Melanoma and Head and Neck Cancer: This study is investigating IO102 HYDROCHLORIDE in combination with another peptide (IO103) and pembrolizumab (an established immunotherapy drug) for patients with resectable melanoma and head and neck squamous cell carcinoma[1].
  2. Phase III Trial for Advanced Melanoma: This large-scale study is comparing IO102 HYDROCHLORIDE in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma[2].
  3. Phase II Trial for Head and Neck Cancer: This study is evaluating IO102 HYDROCHLORIDE as a monotherapy and in combination with IO103 for patients with squamous cell carcinoma of the head and neck[3].

How is IO102 HYDROCHLORIDE Administered?

IO102 HYDROCHLORIDE is typically administered as a subcutaneous injection, which means it’s injected just under the skin[1]. The exact dosage and frequency of administration may vary depending on the specific clinical trial and the condition being treated. In some trials, it’s given every three weeks, with additional doses in the first two treatment cycles[2].

Potential Side Effects

As IO102 HYDROCHLORIDE is still in clinical trials, the full range of potential side effects is not yet known. However, common side effects of immunotherapy drugs may include:

  • Fatigue
  • Skin reactions at the injection site
  • Flu-like symptoms
  • Nausea

More serious side effects can occur but are less common. It’s important to note that the clinical trials are closely monitoring the safety and tolerability of IO102 HYDROCHLORIDE[3].

Future Prospects

The ongoing clinical trials for IO102 HYDROCHLORIDE are promising, particularly in combination with other immunotherapy drugs. Researchers are hopeful that this treatment could improve outcomes for patients with melanoma and head and neck cancers, especially those who don’t respond well to current treatments[2].

If the trials are successful, IO102 HYDROCHLORIDE could become an important new tool in the fight against cancer, potentially offering hope to patients with difficult-to-treat cancers.

Aspect Details
Drug Name IO102 Hydrochloride
Cancer Types Studied Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Administration Method Subcutaneous injection
Trial Phases Phase II and Phase III
Combination Therapies Often combined with pembrolizumab or IO103
Primary Endpoints Pathological response, Progression-free survival
Secondary Endpoints Overall survival, Objective response rate, Safety and tolerability
Patient Eligibility Varies by trial, generally includes specific cancer types and stages, performance status, and prior treatment history

FAQ

  • What is IO102 Hydrochloride? IO102 Hydrochloride is an investigational immunotherapy drug being studied for its potential to treat melanoma and head and neck cancer. It is designed to stimulate the immune system to fight cancer cells.
  • What types of cancer are being studied with IO102 Hydrochloride? Clinical trials are investigating IO102 Hydrochloride for the treatment of melanoma (a type of skin cancer) and squamous cell carcinoma of the head and neck (SCCHN).
  • How is IO102 Hydrochloride administered? IO102 Hydrochloride is typically administered as a subcutaneous injection, which means it is injected just under the skin.
  • Are there any side effects associated with IO102 Hydrochloride? As with any investigational drug, potential side effects are being closely monitored in clinical trials. Common side effects of immunotherapies may include fatigue, skin reactions, and flu-like symptoms. Specific side effects for IO102 Hydrochloride will be better understood as more data becomes available from the trials.
  • How can patients participate in clinical trials involving IO102 Hydrochloride? Patients interested in participating in clinical trials should discuss their options with their oncologist. Eligibility criteria vary for each trial, but generally include factors such as cancer type, stage, previous treatments, and overall health status.

Ongoing Clinical Trials on Io102 Hydrochloride

  • Study on the Effects of IO102 Hydrochloride and IO103 Acetate for Patients with Head and Neck Cancer

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study of IO102-IO103 and Pembrolizumab for Patients with Advanced Melanoma

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Denmark France Germany Hungary +4

Glossary

  • Immunotherapy: A type of cancer treatment that helps your immune system fight cancer cells.
  • Melanoma: A serious type of skin cancer that develops in the cells (melanocytes) that produce melanin, the pigment that gives your skin its color.
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN): A type of cancer that begins in the squamous cells that line the moist, mucosal surfaces inside the head and neck.
  • Clinical Trial: A research study that tests how well new medical approaches work in people, often used to evaluate new treatments for diseases like cancer.
  • Subcutaneous Injection: A method of administering medication by injecting it just under the skin.
  • Neoadjuvant Treatment: Treatment given before the main treatment, usually to shrink a tumor before surgery.
  • Pathological Response: The degree to which a tumor has responded to treatment, as determined by examining tissue samples under a microscope.
  • RECIST: Response Evaluation Criteria In Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.

References

  1. http://clinicaltrials.eu/trial/study-of-io102-io103-and-pembrolizumab-for-patients-with-resectable-melanoma-and-head-and-neck-squamous-cell-carcinoma/
  2. http://clinicaltrials.eu/trial/study-of-io102-io103-and-pembrolizumab-for-patients-with-advanced-melanoma/
  3. http://clinicaltrials.eu/trial/study-on-the-effects-of-io102-hydrochloride-and-io103-acetate-for-patients-with-head-and-neck-cancer/